SEOUL PHARMA CO.,LTD Logo

SEOUL PHARMA CO.,LTD

Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.

018680 | KO

Overview

Corporate Details

ISIN(s):
KR7018680009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 124-31 서울제약 오송공장, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seoul Pharma Co., Ltd. is a pharmaceutical company that manufactures and distributes a range of pharmaceutical products for both domestic and international markets. The company specializes in advanced Drug Delivery System (DDS) technologies, with a particular focus on its Orally Disintegrating Film (ODF) platform. Its product portfolio includes over-the-counter medications and prescription drugs across various therapeutic areas, including vitamins, antibiotics, and treatments for the cardiovascular and circulatory systems. Seoul Pharma operates in compliance with global Good Manufacturing Practice (GMP) standards, aiming to improve global health through its innovative technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 953.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 915.1 KB
2025-04-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 92.8 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.4 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 18.5 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 480.3 KB
2025-03-17 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 14.3 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.2 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 89.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.5 KB
2025-02-07 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.1 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 818.8 KB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 836.4 KB
2024-05-14 00:00
Quarterly Report
분기보고서 (2024.03)
Korean 734.1 KB

Automate Your Workflow. Get a real-time feed of all SEOUL PHARMA CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEOUL PHARMA CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEOUL PHARMA CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.